Atypical Teratoid Rhabdoid Tumors Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)

DelveInsight's, "Atypical Teratoid Rhabdoid Tumors Pipeline Insight 2024" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Atypical Teratoid Rhabdoid Tumors (ATRT) pipeline landscape. It covers the Atypical Teratoid Rhabdoid Tumors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Atypical Teratoid Rhabdoid Tumors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Atypical Teratoid Rhabdoid Tumors Pipeline Report
• DelveInsight's Atypical Teratoid Rhabdoid Tumors pipeline report depicts a robust space with 6+ active players working to develop 6+ pipeline therapies for Atypical Teratoid Rhabdoid Tumors treatment.
• The leading companies working in the Atypical Teratoid Rhabdoid Tumors market include Novartis Pharmaceuticals, Ipsen Pharma, Chimerix, Exelixis, Takeda Pharmaceuticals, and others.
• Promising Atypical Teratoid Rhabdoid Tumors Pipeline Therapies in the various stages of development include alisertib, methotrexate, cisplatin, Tazemetostat, Nivolumab, Ipilimumab, Rifampin, and others.
• April 2024:- Epizyme Inc.- A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma. This is a Phase II, multicenter, open-label, single arm, 2-stage study of tazemetostat 800 mg BID (twice daily) and 1600 mg QD (once daily). Subjects will be screened for eligibility within 21 days of the planned date of the first dose of tazemetostat and enrolled into one of 8 cohorts.
• March 2024:- Sabine Mueller, MD, PhD- A Phase 1 Study of Modified Measles Virus (MV-NIS) for the Treatment of Children and Young Adults With Recurrent Medulloblastoma or Recurrent Atypical Teratoid Rhabdoid Tumors (ATRT). This study will look to determine the safety and recommended phase 2 dose of the modified measles virus (MV-NIS) in children and young adults with recurrent medulloblastoma or atypical teratoid rhabdoid tumor (ATRT).

Request a sample and discover the recent advances in Atypical Teratoid Rhabdoid Tumors Treatment Drugs @ Atypical Teratoid Rhabdoid Tumors Pipeline Report- https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-atrt-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Atypical Teratoid Rhabdoid Tumors pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Atypical Teratoid Rhabdoid Tumors drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Atypical Teratoid Rhabdoid Tumors clinical trial landscape.

Atypical Teratoid Rhabdoid Tumors Overview
ATRT is a primary central nervous system (CNS) tumor. This means it begins in the brain or spinal cord. Genes may be mutated (changed) in many types of cancer, which can increase the growth and spread of cancer cells.

Find out more about Atypical Teratoid Rhabdoid Tumors Treatment Drugs @ Drugs for Atypical Teratoid Rhabdoid Tumors Treatment- https://www.delveinsight.com/sample-request/atypical-teratoid-rhabdoid-tumors-atrt-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Atypical Teratoid Rhabdoid Tumors Emerging Drugs Profile
• Alisertib: Takeda Pharmaceuticals
• ONC206: Chimerix

Atypical Teratoid Rhabdoid Tumors Pipeline Therapeutics Assessment
The Atypical Teratoid Rhabdoid Tumors pipeline report proffers an integral view of the Atypical Teratoid Rhabdoid Tumors emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Learn more about the emerging Atypical Teratoid Rhabdoid Tumors Pipeline Therapies @ Atypical Teratoid Rhabdoid Tumors Clinical Trials Assessment- https://www.delveinsight.com/sample-request/atypical-teratoid-rhabdoid-tumors-atrt-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Atypical Teratoid Rhabdoid Tumors Pipeline Report
• Coverage- Global
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Atypical Teratoid Rhabdoid Tumors Companies- Novartis Pharmaceuticals, Ipsen Pharma, Chimerix, Exelixis, Takeda Pharmaceuticals, and others.
• Atypical Teratoid Rhabdoid Tumors Pipeline Therapies- alisertib, methotrexate, cisplatin, Tazemetostat, Nivolumab, Ipilimumab, Rifampin, and others.

Dive deep into rich insights for new drugs for Atypical Teratoid Rhabdoid Tumors Treatment, Visit @ Atypical Teratoid Rhabdoid Tumors Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/atypical-teratoid-rhabdoid-tumors-atrt-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Atypical Teratoid Rhabdoid Tumors (ATRT): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Atypical Teratoid Rhabdoid Tumors (ATRT)- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name: Company Name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Alisertib: Takeda Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ONC206: Chimerix
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Atypical Teratoid Rhabdoid Tumors (ATRT) Key Companies
21. Atypical Teratoid Rhabdoid Tumors (ATRT) Key Products
22. Atypical Teratoid Rhabdoid Tumors (ATRT)- Unmet Needs
23. Atypical Teratoid Rhabdoid Tumors (ATRT)- Market Drivers and Barriers
24. Atypical Teratoid Rhabdoid Tumors (ATRT)- Future Perspectives and Conclusion
25. Atypical Teratoid Rhabdoid Tumors (ATRT) Analyst Views
26. Atypical Teratoid Rhabdoid Tumors (ATRT) Key Companies
27. Appendix

For further information on the Atypical Teratoid Rhabdoid Tumors Pipeline therapeutics, reach out to Atypical Teratoid Rhabdoid Tumors Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/atypical-teratoid-rhabdoid-tumors-atrt-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/

This release was published on openPR.